Can DES Supplier Strategy, R&D Investments Rival Pharma? Tobin Thinks So
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's early decision to manufacture the Taxus paclitaxel-eluting stent in excess of market demand allowed the firm to restore U.S. inventory levels within 48 hours of the firm's July 16 recall, according to Chairman & CEO Jim Tobin
You may also be interested in...
Boston Scientific’s Tobin: Rising R&D Costs Leave Little Room For Small Firms
The medical device industry will be dominated by an increasingly exclusive club of large, broad-based companies as the cost of innovation shuts out smaller players and fuels further consolidation, Boston Scientific CEO Jim Tobin predicts
Boston Scientific’s Tobin: Rising R&D Costs Leave Little Room For Small Firms
The medical device industry will be dominated by an increasingly exclusive club of large, broad-based companies as the cost of innovation shuts out smaller players and fuels further consolidation, Boston Scientific CEO Jim Tobin predicts
Boston Scientific Retains Right To Absorb Reva Medical Under Equity Deal
Reva Medical's unique slide-and-lock bioabsorbable stent design has attracted equity investment from Boston Scientific, which previously expressed doubts about the viability of the biodegradable stent concept